Free Trial
NASDAQ:FGEN

FibroGen (FGEN) Stock Price, News & Analysis

FibroGen logo
$0.50 +0.02 (+3.88%)
(As of 12/24/2024 05:19 PM ET)

About FibroGen Stock (NASDAQ:FGEN)

Key Stats

Today's Range
$0.48
$0.55
50-Day Range
$0.30
$0.48
52-Week Range
$0.18
$2.93
Volume
2.22 million shs
Average Volume
2.11 million shs
Market Capitalization
$50.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FibroGen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
55th Percentile Overall Score

FGEN MarketRank™: 

FibroGen scored higher than 55% of companies evaluated by MarketBeat, and ranked 507th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for FibroGen are expected to grow in the coming year, from ($0.86) to ($0.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of FibroGen is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of FibroGen is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    3.41% of the outstanding shares of FibroGen have been sold short.
  • Short Interest Ratio / Days to Cover

    FibroGen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in FibroGen has recently decreased by 11.79%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    FibroGen does not currently pay a dividend.

  • Dividend Growth

    FibroGen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.41% of the outstanding shares of FibroGen have been sold short.
  • Short Interest Ratio / Days to Cover

    FibroGen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in FibroGen has recently decreased by 11.79%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    FibroGen has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for FibroGen this week, compared to 2 articles on an average week.
  • Search Interest

    Only 6 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, FibroGen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.98% of the stock of FibroGen is held by insiders.

  • Percentage Held by Institutions

    72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about FibroGen's insider trading history.
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Stock News Headlines

FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
HC Wainwright Forecasts FibroGen FY2026 Earnings
Brokers Offer Predictions for FibroGen FY2024 Earnings
FibroGen initiated with a Buy at H.C. Wainwright
See More Headlines

FGEN Stock Analysis - Frequently Asked Questions

FibroGen's stock was trading at $0.8863 at the beginning of 2024. Since then, FGEN shares have decreased by 43.7% and is now trading at $0.4986.
View the best growth stocks for 2024 here
.

FibroGen, Inc. (NASDAQ:FGEN) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.21. The biopharmaceutical company earned $46.33 million during the quarter, compared to analysts' expectations of $34 million.

FibroGen (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen's top institutional shareholders include Primecap Management Co. CA (9.87%), GSA Capital Partners LLP (1.09%), Geode Capital Management LLC (1.08%) and Assenagon Asset Management S.A. (0.77%). Insiders that own company stock include Thane Wettig, Christine Chung, Mark Eisner, Deyaa Adib, James A Schoeneck, Juan Graham and Benjamin Cravatt.
View institutional ownership trends
.

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

Last Earnings
11/12/2024
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FGEN
Employees
486
Year Founded
N/A

Profitability

Net Income
$-284,230,000.00
Pretax Margin
-69.56%

Debt

Sales & Book Value

Annual Sales
$180.02 million
Book Value
($1.87) per share

Miscellaneous

Free Float
98,775,000
Market Cap
$50.24 million
Optionable
Optionable
Beta
0.82

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:FGEN) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners